Breaking News
Get 40% Off 0
💰 Warren Buffett reveals a $6.72 billion stake in Chubb Copy Portfolios
Close

Genexine Inc (095700)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7,160 +40    +0.56%
02:40:51 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7095700001 
  • Volume: 75,203
  • Bid/Ask: 7,160 / 7,170
  • Day's Range: 7,150 - 7,370
Genexine 7,160 +40 +0.56%

095700 Balance Sheet

 
Featured here, the Balance Sheet for Genexine Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 92159.74 123348.53 117364.05 122046.41
Cash and Short Term Investments 64482.2 89851.8 80165.61 87827.83
Cash - - - -
Cash & Equivalents 6031.99 2532.19 59545.52 82988.88
Short Term Investments 14000 17000 17000 -
Total Receivables, Net 12532.21 12455.13 12743.61 11150.01
Accounts Receivables - Trade, Net 10723.55 9891.42 8895.01 9080.24
Total Inventory - - - -
Prepaid Expenses 2621.78 629.91 756.49 591.44
Other Current Assets, Total 12523.55 20411.69 23698.34 22477.12
Total Assets 376586.6 393028.76 417557.46 439855.17
Property/Plant/Equipment, Total - Net 114208.79 113784.24 109473.45 110113.63
Property/Plant/Equipment, Total - Gross 133240.55 131889.95 126570.37 126102.83
Accumulated Depreciation, Total -19031.77 -18105.71 -17096.93 -15989.2
Goodwill, Net - - - -
Intangibles, Net 2016.51 1922.11 1930.49 1983.35
Long Term Investments 160438.78 147580.35 173088.12 199323.08
Note Receivable - Long Term 1684.2 2515.67 3848.61 1169.76
Other Long Term Assets, Total 7760.74 6393.54 15701.36 6388.7
Other Assets, Total 58568.03 95324.21 31574.81 17066.08
Total Current Liabilities 54526.28 72280.08 76283.84 69920.56
Accounts Payable - - - -
Payable/Accrued - - - -
Accrued Expenses 1375.08 735.25 657.72 1084.74
Notes Payable/Short Term Debt 44575.04 58587.08 58119.83 56673.2
Current Port. of LT Debt/Capital Leases 118.12 113.55 144.79 145.01
Other Current liabilities, Total 8458.04 12844.21 17361.5 12017.61
Total Liabilities 79682.98 97387.77 95687.18 98238.18
Total Long Term Debt 22734.02 22182.84 16638.35 17659.97
Long Term Debt 22681.44 22085.67 16528.17 17505.7
Capital Lease Obligations 52.59 97.17 110.18 154.27
Deferred Income Tax - - - -
Minority Interest 281.81 1202.03 1201.58 4758.7
Other Liabilities, Total -42434.17 -56864.26 -56556.42 -50774.24
Total Equity 296903.62 295640.99 321870.28 341616.98
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 20755.3 20755.3 20755.3 20158.37
Additional Paid-In Capital 645956.41 652889.67 652889.67 643162.86
Retained Earnings (Accumulated Deficit) -336613.76 -323909.35 -302975 -263720.65
Treasury Stock - Common -938.89 -938.89 -938.89 -938.89
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -32255.44 -53155.73 -47860.8 -57044.72
Total Liabilities & Shareholders' Equity 376586.6 393028.76 417557.46 439855.17
Total Common Shares Outstanding 41.45 41.45 40.84 40.26
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

095700 Comments

Write your thoughts about Genexine Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
민균 손
민균 손 Jan 21, 2021 5:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.kalbe.co.id/news-and-events/ArtMID/443/ArticleID/895/Optimism-in-the-Midst-of-a-Pandemic
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email